Health experts are raising alarms over a new study suggesting that commonly prescribed medications may increase the risk of dementia, particularly with long-term use. The research, conducted by the University of Nottingham with funding from the National Institute for Health Research (NIHR), indicates that drugs frequently prescribed for bladder issues, Parkinson’s disease, and depression could significantly heighten dementia risk.
The study focused on patients aged 55 and older, revealing a startling nearly 50% increase in dementia risk among those who used potent anticholinergic medications for at least three years. These drugs, which block the neurotransmitter acetylcholine in the nervous system, are prescribed for conditions ranging from chronic obstructive pulmonary disease (COPD) to bladder disorders, allergies, gastrointestinal issues, and Parkinson’s disease symptoms.
The Alzheimer’s Society responded to the findings, emphasizing that their own research has shown a strong link between anticholinergic drugs and dementia risk. “This study builds on this information, showing that long-term, high-dose use increases risk of some dementias, particularly vascular dementia,” said a spokesperson for the organization.
However, they also pointed out the limitations of the study, acknowledging that it is impossible to determine whether the diseases causing dementia were already present in patients’ brains before they began taking these medications. The findings have prompted calls for healthcare providers to reconsider their prescribing practices, particularly for older individuals.
According to Surrey Live, healthcare guidelines currently advise doctors to avoid anticholinergic drugs for frail older people due to their impact on memory and cognition. However, given the new evidence, doctors are urged to reassess the risks for all middle-aged and older patients, as prolonged use could increase dementia risk.
The study, led by Professor Carol Coupland from the University of Nottingham’s Division of Primary Care, analyzed medical records from 58,769 dementia patients and 225,574 patients without dementia, all aged 55 or older. The research, published in JAMA Internal Medicine, found an increased dementia risk specifically with anticholinergic antidepressants, antipsychotic drugs, antiparkinson drugs, bladder medications, and epilepsy drugs. Interestingly, other anticholinergic medications, like antihistamines and gastrointestinal drugs, did not show the same association.
While the study raises concerns about the long-term use of these medications, experts caution against abruptly discontinuing them. Patients who are concerned about the risks should consult their doctors to evaluate their treatment plans. Professor Tom Dening, Head of the Centre for Dementia at the University of Nottingham, noted that the average age of the dementia patients studied was 82, with women comprising 63% of the group.
Professor Coupland stressed the importance of healthcare providers considering the risks and benefits of anticholinergic medications. “Our study adds further evidence of the potential risks associated with strong anticholinergic drugs,” he said, emphasizing the need for alternative treatments when possible.
The study highlights the importance of regular medication reviews, particularly for individuals diagnosed with dementia before the age of 80. It serves as a reminder to approach the prescription of anticholinergic drugs with caution, especially for middle-aged and older individuals.